Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13459001 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL30977009 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL30977016 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL30977013 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL4114380 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL490850 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL9492675 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL30977026 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL30977023 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL28052002 | 0.98 | MEN1 (0.47) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024090423-A1 | (METH)ACRYLATE-CONTAINING COMPOSITION | 株式会社日本触媒 | 2024-05-02 | — | — | WO | disclosed |
| EP-3169671-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-05-24 | — | — | EP | disclosed |
| CN-103155164-B | Method for manufacturing solar cell | 日立化成株式会社 | 2016-08-10 | — | — | CN | disclosed |
| US-9382179-B2 | Nickel modified catalyst for the production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEMICAL COMPANY (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2016008433-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-01-21 | — | — | WO | disclosed |
| US-9056313-B2 | Catalysts for the production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEMICAL COMPANY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9000229-B2 | Production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEMICAL COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2015043492-A1 | SUBSTITUTED UREA DERIVATIVES AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-04-02 | — | — | WO | disclosed |
| US-20140303404-A1 | NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785697-B2 | Nickel modified catalyst for the production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEMICAL COMPANY (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2728624-A1 | SEMICONDUCTOR SUBSTRATE, MANUFACTURING METHOD THEREFOR, SOLAR-CELL ELEMENT, AND SOLAR CELL | Hitachi Chemical Company, Ltd. (JP) | 2014-05-07 | — | — | EP | disclosed |
| CN-103764605-A | Nickel modified catalyst for the production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEM CO | 2014-04-30 | — | — | CN | disclosed |
| CN-103608322-A | Production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEM CO | 2014-02-26 | — | — | CN | disclosed |
| US-20120330068-A1 | NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012177602-A1 | PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177591-A1 | NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177484-A1 | CATALYSTS FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120330066-A1 | PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120330067-A1 | CATALYSTS FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2128865-B1 | Optical recording composition, holographic recording medium, and method of recording and reproducing information | FUJIFILM CORP (JP) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330068-A1 | NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | KAT5, HRH3, KAT8 | MEN1 632/4885KMT2A 101/4885THRB 4695/4885 |
| US-20120330067-A1 | CATALYSTS FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | SUV39H2, KAT5, SUV39H1 | MEN1 2262/4885KMT2A 59/4885THRB 4695/4885 |
| US-20120330066-A1 | PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | SUV39H1, HDHD5, SUV39H2 | MEN1 1778/4885KMT2A 133/4885THRB 4164/4885 |
| US-20140303404-A1 | NICKEL MODIFIED CATALYST FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | KAT5, HRH3, KAT8 | MEN1 632/4885KMT2A 101/4885THRB 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.